Literature DB >> 8813110

Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma.

W C Lee1, B Balsara, Z Liu, S C Jhanwar, J R Testa.   

Abstract

Previous cytogenetic analysis has revealed frequent losses of chromosome 1p21-22 in human malignant mesothelioma, suggesting that the loss or inactivation of a tumor suppressor gene's) residing at this site may contribute to the tumorigenic conversion of mesothelial cells. To more precisely define the location of the target gene, primary tumor specimens and cell lines from 50 malignant mesotheliomas were examined for loss of heterozygosity using short tandem repeat polymorphism (STRP) markers. Nineteen STRP markers established by the Cooperative Human Linkage Center were selected for the initial screening of the entire short arm of chromosome 1. Thirty-seven cases (74%) showed allelic losses at least at one locus in 1p. Thirty-six of these cases showed losses of 1p21-22, including 23 with partial deletions involving this region. To obtain a higher resolution map of this region, another 13 STRP markers from the Genethon map were used to define the shortest region of overlapping deletions to a 4-cM segment flanked by the loci D1S435 and D1S236. The chromosomal location of the critically deleted region was confirmed to be within 1p22 by karyotypic and fluorescence in situ hybridization analyses.

Entities:  

Mesh:

Year:  1996        PMID: 8813110

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Aggressive mucosa associated lymphoid tissue lymphomas are associated with mutations in Bcl10.

Authors:  J Spencer
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

Authors:  H Dannenberg; E J Speel; J Zhao; P Saremaslani; E van Der Harst; J Roth; P U Heitz; H J Bonjer; W N Dinjens; W J Mooi; P Komminoth; R R de Krijger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma.

Authors:  Domenico Coppola; James Helm; Msoumeh Ghayouri; Mokenge P Malafa; Hong-Gang Wang
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

Review 4.  Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

Authors:  J F Lechner; J Tesfaigzi; B I Gerwin
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

5.  Bax-interacting factor-1 expression in prostate cancer.

Authors:  Domenico Coppola; Cecilia Oliveri; Zena Sayegh; David Boulware; Yoshinori Takahashi; Julio Pow-Sang; Julie Y Djeu; Hong-Gang Wang
Journal:  Clin Genitourin Cancer       Date:  2008-09       Impact factor: 2.872

Review 6.  Autophagy genes as tumor suppressors.

Authors:  Chengyu Liang; Jae U Jung
Journal:  Curr Opin Cell Biol       Date:  2009-11-28       Impact factor: 8.382

7.  Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma.

Authors:  Domenico Coppola; Farah Khalil; Steven A Eschrich; David Boulware; Timothy Yeatman; Hong-Gang Wang
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

8.  Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis.

Authors:  A M Björkqvist; M Wolf; S Nordling; L Tammilehto; A Knuuttila; J Kere; K Mattson; S Knuutila
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

9.  Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Authors:  Neetu Kalra; Jingli Zhang; Anish Thomas; Liqiang Xi; Mitchell Cheung; Jacqueline Talarchek; Sandra Burkett; Maria G Tsokos; Yuanbin Chen; Mark Raffeld; Markku Miettinen; Ira Pastan; Joseph R Testa; Raffit Hassan
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

Review 10.  Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Authors:  Noushin Nabavi; Jingchao Wei; Dong Lin; Colin C Collins; Peter W Gout; Yuzhuo Wang
Journal:  Front Genet       Date:  2018-07-04       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.